{"id":"NCT03176134","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","officialTitle":"A Phase III Randomized, Active-comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator, in Subjects From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-20","primaryCompletion":"2023-07-06","completion":"2023-07-06","firstPosted":"2017-06-05","resultsPosted":"2024-07-03","lastUpdate":"2025-07-31"},"enrollment":100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Bacterial Skin and Skin Structure Infections"],"interventions":[{"type":"DRUG","name":"Tedizolid phosphate","otherNames":["MK-1986","TR-701 FA"]},{"type":"DRUG","name":"Comparator","otherNames":[]}],"arms":[{"label":"Cohort 1: Tedizolid phosphate 6 to <12 Years","type":"EXPERIMENTAL"},{"label":"Cohort 1: Comparator 6 to <12 Years","type":"ACTIVE_COMPARATOR"},{"label":"Cohort 2: Tedizolid phosphate 2 to <6 Years","type":"EXPERIMENTAL"},{"label":"Cohort 2: Comparator 2 to <6 Years","type":"ACTIVE_COMPARATOR"},{"label":"Cohort 3: Tedizolid phosphate 28 Days to <2 Years","type":"EXPERIMENTAL"},{"label":"Cohort 3: Comparator 28 Days to <2 Years","type":"ACTIVE_COMPARATOR"},{"label":"Cohort 4: Tedizolid phosphate Birth to <28 Days Term and Preterm Neonates","type":"EXPERIMENTAL"},{"label":"Cohort 4: Comparator Birth to <28 Days Term and Preterm Neonates","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety, tolerability, and efficacy of tedizolid phosphate (MK-1986) compared with comparator antibacterial agent in participants from birth to less than 12 years of age with acute bacterial skin and skin structure infections (ABSSSI).","primaryOutcome":{"measure":"Number of Participants Who Experienced an Adverse Event (AE)","timeFrame":"Up to approximately 35 days","effectByArm":[{"arm":"Cohort 1: Tedizolid Phosphate 6 to <12 Years","deltaMin":7,"sd":null},{"arm":"Cohort 1: Comparator 6 to <12 Years","deltaMin":2,"sd":null},{"arm":"Cohort 2: Tedizolid Phosphate 2 to <6 Years","deltaMin":7,"sd":null},{"arm":"Cohort 2: Comparator 2 to <6 Years","deltaMin":2,"sd":null},{"arm":"Cohort 3: Tedizolid Phosphate 28 Days to <2 Years","deltaMin":7,"sd":null},{"arm":"Cohort 3: Comparator 28 Days to <2 Years","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Day","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":22},"locations":{"siteCount":58,"countries":["United States","Brazil","Bulgaria","Georgia","Germany","Guatemala","Latvia","Lithuania","Mexico","Poland","Russia","South Africa","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["40233296"],"seeAlso":["https://www.merckclinicaltrials.com/","https://msd.trialsummaries.com/Study/StudyDetails?id=26090&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":44},"commonTop":["Diarrhoea","Nausea","Vomiting","Folliculitis","Upper respiratory tract infection"]}}